\-\ Texto\\:\\ \ \(0\)\
\-\ located\\ in\\ the\\ left\\ lateral\\ convexity\\ of\\ the\\ cranial\\ vault\\ is\\ a\\ well\\-\\ circumscribed\\,\\ peripherally\\ based\\,\\ extra\\-axial\\ lesion\\ that\\ is\\ nearly\\ isointense\\ to\\ cerebral\\ cortex\\ on\\ both\\ t1\\ and\\ t2\\ imaging\\ sequences\\.\\ the\\ lesion\\ also\\ demonstrates\\ intense\\ homogeneous\\ enhancement\\ following\\ administration\\ of\\ gadolinium\\.\\ there\\ is\\ evident\\ thickening\\ and\\ abnormal\\ enhancement\\ of\\ the\\ adjacent\\ meninges\\ consistent\\ with\\ a\\ \\‚\\Ä\\údural\\ tail\\ sign\\,\\"\\ which\\ is\\ most\\ commonly\\ associated\\ with\\ a\\ meningioma\ \(0\)\
\-\ meningioma\ \(167\)\
\-\ 70\\ yo\\ man\\ with\\ a\\ 3\\ month\\ history\\ of\\ transient\\ episodes\\ of\\ right\\ upper\\ extremity\\ weakness\\,\\ dysarthria\\,\\ and\\ expressive\\ aphasia\\ which\\ was\\ refractory\\ to\\ aspirin\\ and\\ ticlopidine\\ therapy\\.\\ past\\ medical\\ history\\ was\\ significant\\ only\\ for\\ hypertension\\.\\ on\\ admission\\,\\ ct\\ \\(without\\ contrast\\)\\ was\\ negative\\ for\\ hemorrhage\\ and\\ masses\\.\ \(0\)\
\-\ meningiomas\\ account\\ for\\ 13\\ to\\ 18\\ percent\\ of\\ intracranial\\ tumors\\.\\ they\\ demonstrate\\ a\\ female\\ predominance\\,\\ and\\ occur\\ primarily\\ in\\ adults\\ from\\ ages\\ 20\\ to\\ 60\\,\\ with\\ a\\ peak\\ age\\ of\\ 45\\ years\\.\\ \\ clinical\\ symptoms\\ are\\ usually\\ nonspecific\\,\\ consisting\\ of\\ headache\\,\\ visual\\ impairment\\,\\ and\\ seizures\\,\\ but\\ focal\\ weakness\\ and\\ numbness\\ in\\ an\\ opposite\\ extremity\\ may\\ be\\ present\\ if\\ the\\ mass\\ compresses\\ the\\ brain\\ around\\ the\\ rolandic\\ fissure\\.\\ \ \(0\)\
\-\ meningiomas\\ are\\ normally\\ benign\\ tumors\\ \\(who\\ grade\\ 1\\)\\ arising\\ from\\ meningothelial\\ cells\\ \\(arachnoid\\ villi\\)\\.\\ the\\ parasagittal\\ region\\ is\\ the\\ most\\ frequent\\ site\\ for\\ meningiomas\\,\\ followed\\ by\\ the\\ cranial\\ convexity\\,\\ sphenoid\\ wings\\,\\ parasellar\\ region\\,\\ olfactory\\ groove\\,\\ cerebellopontine\\ angle\\,\\ and\\ the\\ intraventricular\\ region\\ \\(rare\\)\\.\\ ninety\\ percent\\ of\\ meningiomas\\ are\\ supratentorial\\,\\ with\\ two\\ thirds\\ occurring\\ in\\ the\\ anterior\\ half\\ of\\ the\\ skull\\.\\ \\ lesions\\ are\\ usually\\ single\\,\\ but\\ in\\ 1\\ to\\ 2\\ percent\\ of\\ cases\\ they\\ are\\ multiple\\.\\ multiple\\ meningiomas\\ are\\ usually\\ seen\\ in\\ association\\ with\\ neurofibromatosis\\ type\\ 2\\.\\ \ \(0\)\
\-\ blood\\ supply\\ to\\ the\\ lesion\\ usually\\ comes\\ from\\ meningeal\\ branches\\ of\\ the\\ external\\ carotid\\ artery\\ or\\,\\ less\\ commonly\\,\\ from\\ meningeal\\ branches\\ of\\ the\\ internal\\ carotid\\ and\\ vertebral\\ arteries\\.\ \(0\)\
\-\ on\\ mri\\,\\ the\\ majority\\ of\\ meningiomas\\ have\\ a\\ signal\\ intensity\\ similar\\ to\\ that\\ of\\ gray\\ matter\\ on\\ all\\ sequences\\.\\ densely\\ calcified\\ lesions\\ may\\ be\\ hypointense\\ on\\ imaging\\.\\ t1\\-weighted\\ \\ images\\ often\\ provide\\ the\\ best\\ description\\ of\\ anatomic\\ distortion\\ and\\ displacement\\ of\\ cerebral\\ cortex\\ and\\ adjacent\\ white\\ matter\\ \\(white\\ matter\\ buckling\\)\\,\\ a\\ sign\\ of\\ an\\ extra\\-axial\\ lesion\\.\\ an\\ interface\\ between\\ brain\\ parenchyma\\ and\\ lesion\\ can\\ often\\ be\\ identified\\;\\ this\\ may\\ be\\ related\\ to\\ a\\ csf\\ cleft\\,\\ a\\ vascular\\ rim\\,\\ or\\ a\\ dural\\ margin\\.\\ a\\ csf\\ cleft\\ sign\\ is\\ best\\ seen\\ as\\ a\\ rim\\ of\\ hyperintensity\\ on\\ t2\\-weighted\\ images\\.\ \(0\)\
\-\ meningiomas\\ show\\ intense\\ enhancement\\ with\\ gadolinium\\ and\\ are\\ sharply\\ circumscribed\\.\\ they\\ have\\ a\\ characteristic\\ broad\\ base\\ of\\ dural\\ attachment\\,\\ but\\ this\\ may\\ be\\ evident\\ only\\ with\\ imaging\\ in\\ sagittal\\ or\\ coronal\\ planes\\.\\ an\\ enhancing\\ \\‚\\Ä\\údural\\ tail\\‚\\Ä\\ù\\ may\\ be\\ seen\\ in\\ up\\ to\\ 60\\ percent\\ of\\ meningiomas\\.\\ in\\ the\\ majority\\ of\\ cases\\,\\ this\\ is\\ a\\ reactive\\ phenomenon\\ and\\ does\\ not\\ represent\\ tumor\\ extension\\ to\\ the\\ dura\\.\\ mass\\ effect\\ may\\ be\\ mild\\ and\\ less\\ than\\ would\\ he\\ expected\\ for\\ the\\ size\\ of\\ the\\ tumor\\.\\ this\\ is\\ explained\\ by\\ resulting\\ local\\ pressure\\ atrophy\\ occurring\\ at\\ a\\ rate\\ similar\\ to\\ tumor\\ growth\\.\\ \ \(0\)\
\-\ meningiomas\\ may\\ erode\\ adjacent\\ bone\\ or\\ stimulate\\ new\\ bone\\ formation\\.\\ \\ hyperostosis\\ may\\ or\\ may\\ not\\ be\\ associated\\ with\\ bone\\ invasion\\ by\\ meningioma\\ cells\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ meningiomas\\:\\ 0\\.0886751871522782\ \(0\)\
\-\ percent\\:\\ 0\\.03205945157044286\ \(0\)\
\-\ may\\:\\ 0\\.029034346506167152\ \(0\)\
\-\ dural\\:\\ 0\\.028521098722923178\ \(0\)\
\-\ meningeal\\:\\ 0\\.018754638877728137\ \(0\)\
\-\ convexity\\:\\ 0\\.018207083990878958\ \(0\)\
\-\ be\\:\\ 0\\.01814467088941727\ \(0\)\
\-\ usually\\:\\ 0\\.017865254759839994\ \(0\)\
\-\ matter\\:\\ 0\\.017372529967646117\ \(0\)\
\-\ meningioma\\:\\ 0\\.016967759052263727\ \(0\)\
\-\ occurring\\:\\ 0\\.016428458368784676\ \(0\)\
\-\ tail\\:\\ 0\\.016194989878806153\ \(0\)\
\-\ branches\\:\\ 0\\.016083936996815717\ \(0\)\
\-\ they\\:\\ 0\\.01589817277015821\ \(0\)\
\-\ extra\\-axial\\:\\ 0\\.01567242184827946\ \(0\)\
\-\ intense\\:\\ 0\\.015576795121576963\ \(0\)\
\-\ sign\\:\\ 0\\.015286298632172485\ \(0\)\
\-\ ticlopidine\\:\\ 0\\.015173009335570566\ \(0\)\
\-\ rolandic\\:\\ 0\\.015173009335570566\ \(0\)\
\-\ lesion\\:\\ 0\\.014978960636836958\ \(0\)\
\-\ majority\\:\\ 0\\.014459201057229738\ \(0\)\
\-\ cleft\\:\\ 0\\.014358442426248282\ \(0\)\
\-\ are\\:\\ 0\\.014034624970236166\ \(0\)\
\-\ meningothelial\\:\\ 0\\.01397998492841059\ \(0\)\
\-\ ninety\\:\\ 0\\.01397998492841059\ \(0\)\
\-\ gadolinium\\:\\ 0\\.013952993078033537\ \(0\)\
\-\ adjacent\\:\\ 0\\.013950961673670915\ \(0\)\
\-\ evident\\:\\ 0\\.01346039120663707\ \(0\)\
\-\ well\\-\\:\\ 0\\.013282110387776916\ \(0\)\
\-\ carotid\\:\\ 0\\.013190746307257013\ \(0\)\
\-\ circumscribed\\:\\ 0\\.013074831625306623\ \(0\)\
\-\ \\,\\:\\ 0\\.013046268217700597\ \(0\)\
\-\ 60\\:\\ 0\\.012832778274471995\ \(0\)\
\-\ cranial\\:\\ 0\\.012790540434224784\ \(0\)\
\-\ erode\\:\\ 0\\.012786960521250616\ \(0\)\
\-\ cortex\\:\\ 0\\.012586792167820892\ \(0\)\
\-\ region\\:\\ 0\\.01246265693927356\ \(0\)\
\-\ rim\\:\\ 0\\.0124510202846839\ \(0\)\
\-\ villi\\:\\ 0\\.01240289244669948\ \(0\)\
\-\ best\\:\\ 0\\.012375774867084934\ \(0\)\
\-\ sequences\\:\\ 0\\.012283973672309854\ \(0\)\
\-\ csf\\:\\ 0\\.012283973672309854\ \(0\)\
\-\ wings\\:\\ 0\\.012089085980616941\ \(0\)\
\-\ enhancement\\:\\ 0\\.011826964368965763\ \(0\)\
\-\ parasellar\\:\\ 0\\.011823766393995155\ \(0\)\
\-\ cells\\:\\ 0\\.011794997225989664\ \(0\)\
\-\ parasagittal\\:\\ 0\\.01159393611409064\ \(0\)\
\-\ similar\\:\\ 0\\.011537647569503918\ \(0\)\
\-\ expressive\\:\\ 0\\.011391211439983267\ \(0\)\
\-\ stimulate\\:\\ 0\\.011391211439983267\ \(0\)\
\-\ commonly\\:\\ 0\\.0110999361220504\ \(0\)\
\-\ tumors\\:\\ 0\\.01104893754791911\ \(0\)\
\-\ thirds\\:\\ 0\\.011045822979635331\ \(0\)\
\-\ buckling\\:\\ 0\\.011045822979635331\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.010986233796141687\ \(0\)\
\-\ bone\\:\\ 0\\.010964378733871962\ \(0\)\
\-\ weakness\\:\\ 0\\.010924651817653647\ \(0\)\
\-\ a\\:\\ 0\\.010921853406364234\ \(0\)\
\-\ olfactory\\:\\ 0\\.010758294434604064\ \(0\)\
\-\ extremity\\:\\ 0\\.010757862201867256\ \(0\)\
\-\ vault\\:\\ 0\\.01063074198683518\ \(0\)\
\-\ groove\\:\\ 0\\.01063074198683518\ \(0\)\
\-\ densely\\:\\ 0\\.01063074198683518\ \(0\)\
\-\ imaging\\:\\ 0\\.010337730590992786\ \(0\)\
\-\ meninges\\:\\ 0\\.010296566402599454\ \(0\)\
\-\ tumor\\:\\ 0\\.010286913777680609\ \(0\)\
\-\ dysarthria\\:\\ 0\\.010198187032823294\ \(0\)\
\-\ cerebral\\:\\ 0\\.010190865754781656\ \(0\)\
\-\ less\\:\\ 0\\.00996192772572352\ \(0\)\
\-\ opposite\\:\\ 0\\.009932867446201506\ \(0\)\
\-\ explained\\:\\ 0\\.009932867446201506\ \(0\)\
\-\ compresses\\:\\ 0\\.009852798572475356\ \(0\)\
\-\ cases\\:\\ 0\\.009799693163446239\ \(0\)\
\-\ white\\:\\ 0\\.00975595253945617\ \(0\)\
\-\ aspirin\\:\\ 0\\.009632775557828394\ \(0\)\
\-\ comes\\:\\ 0\\.009632775557828394\ \(0\)\
\-\ phenomenon\\:\\ 0\\.009632775557828394\ \(0\)\
\-\ hyperostosis\\:\\ 0\\.009632775557828394\ \(0\)\
\-\ description\\:\\ 0\\.00956527002744409\ \(0\)\
\-\ supratentorial\\:\\ 0\\.009500312492189621\ \(0\)\
\-\ sharply\\:\\ 0\\.009500312492189621\ \(0\)\
\-\ but\\:\\ 0\\.009410516184338405\ \(0\)\
\-\ often\\:\\ 0\\.009385451113664896\ \(0\)\
\-\ cerebellopontine\\:\\ 0\\.009318969091745857\ \(0\)\
\-\ dura\\:\\ 0\\.009318969091745857\ \(0\)\
\-\ aphasia\\:\\ 0\\.009262532219417129\ \(0\)\
\-\ consisting\\:\\ 0\\.009262532219417129\ \(0\)\
\-\ predominance\\:\\ 0\\.00920788729977069\ \(0\)\
\-\ attachment\\:\\ 0\\.00920788729977069\ \(0\)\
\-\ refractory\\:\\ 0\\.009103541995439479\ \(0\)\
\-\ interface\\:\\ 0\\.009103541995439479\ \(0\)\
\-\ brain\\:\\ 0\\.008851468238563726\ \(0\)\
\-\ only\\:\\ 0\\.008844790562770863\ \(0\)\
\-\ peripherally\\:\\ 0\\.008781319031432342\ \(0\)\
\-\ impairment\\:\\ 0\\.008781319031432342\ \(0\)\
\-\ distortion\\:\\ 0\\.008739843039041531\ \(0\)\
\-\ seen\\:\\ 0\\.008719247582105114\ \(0\)\
\-\ from\\:\\ 0\\.008719006631010068\ \(0\)\
\-\ or\\:\\ 0\\.008618956531529325\ \(0\)\
\-\ intraventricular\\:\\ 0\\.008546249263780448\ \(0\)\
\-\ planes\\:\\ 0\\.00843975115066842\ \(0\)\
\-\ peak\\:\\ 0\\.008372245620284114\ \(0\)\
\-\ ages\\:\\ 0\\.008339460431005813\ \(0\)\
\-\ account\\:\\ 0\\.008307288085029646\ \(0\)\
\-\ provide\\:\\ 0\\.00824469317251523\ \(0\)\
\-\ sphenoid\\:\\ 0\\.008184295031704095\ \(0\)\
\-\ supply\\:\\ 0\\.008184295031704095\ \(0\)\
\-\ an\\:\\ 0\\.00813538632898265\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.008125944684585882\ \(0\)\
\-\ nearly\\:\\ 0\\.008097494939403076\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.008097494939403076\ \(0\)\
\-\ to\\:\\ 0\\.008085626837991133\ \(0\)\
\-\ t1\\-weighted\\:\\ 0\\.008069507812257154\ \(0\)\
\-\ transient\\:\\ 0\\.007961899624681709\ \(0\)\
\-\ fissure\\:\\ 0\\.007885390566900583\ \(0\)\
\-\ lesions\\:\\ 0\\.00787456284455748\ \(0\)\
\-\ half\\:\\ 0\\.007764979915253577\ \(0\)\
\-\ is\\:\\ 0\\.0077423859330082705\ \(0\)\
\-\ primarily\\:\\ 0\\.007719079317866037\ \(0\)\
\-\ broad\\:\\ 0\\.007630794818059581\ \(0\)\
\-\ atrophy\\:\\ 0\\.007588294624272367\ \(0\)\
\-\ nonspecific\\:\\ 0\\.0075674316973664375\ \(0\)\
\-\ adults\\:\\ 0\\.007506318636339054\ \(0\)\
\-\ on\\:\\ 0\\.00747563868191492\ \(0\)\
\-\ t2\\-weighted\\:\\ 0\\.00744730129816585\ \(0\)\
\-\ anatomic\\:\\ 0\\.007428070143952209\ \(0\)\
\-\ arachnoid\\:\\ 0\\.007390240700374282\ \(0\)\
\-\ frequent\\:\\ 0\\.007353224856620473\ \(0\)\
\-\ by\\:\\ 0\\.007347009827426204\ \(0\)\
\-\ episodes\\:\\ 0\\.007264025084048035\ \(0\)\
\-\ normally\\:\\ 0\\.007246726743508445\ \(0\)\
\-\ isointense\\:\\ 0\\.007229600528614869\ \(0\)\
\-\ gray\\:\\ 0\\.007195851008152948\ \(0\)\
\-\ expected\\:\\ 0\\.007162750557330422\ \(0\)\
\-\ association\\:\\ 0\\.0071464360238458376\ \(0\)\
\-\ invasion\\:\\ 0\\.007082681683604272\ \(0\)\
\-\ 70\\:\\ 0\\.007067105374619904\ \(0\)\
\-\ numbness\\:\\ 0\\.007067105374619904\ \(0\)\
\-\ 1\\:\\ 0\\.0069994022993449465\ \(0\)\
\-\ hypointense\\:\\ 0\\.006976496539016768\ \(0\)\
\-\ homogeneous\\:\\ 0\\.006961848191911934\ \(0\)\
\-\ reactive\\:\\ 0\\.006961848191911934\ \(0\)\
\-\ associated\\:\\ 0\\.006941351331868165\ \(0\)\
\-\ margin\\:\\ 0\\.006918636623700098\ \(0\)\
\-\ angle\\:\\ 0\\.006904470532243101\ \(0\)\
\-\ 45\\:\\ 0\\.006795153138573005\ \(0\)\
\-\ most\\:\\ 0\\.006791170883745529\ \(0\)\
\-\ local\\:\\ 0\\.0067558851906105765\ \(0\)\
\-\ visual\\:\\ 0\\.006667600690804121\ \(0\)\
\-\ 13\\:\\ 0\\.006643186516979755\ \(0\)\
\-\ this\\:\\ 0\\.0066171236716979906\ \(0\)\
\-\ in\\:\\ 0\\.006527667936768149\ \(0\)\
\-\ admission\\:\\ 0\\.006481346672490467\ \(0\)\
\-\ represent\\:\\ 0\\.00645942063845014\ \(0\)\
\-\ resulting\\:\\ 0\\.00645942063845014\ \(0\)\
\-\ growth\\:\\ 0\\.006395270217112392\ \(0\)\
\-\ 18\\:\\ 0\\.006384807142970598\ \(0\)\
\-\ have\\:\\ 0\\.00636983847974214\ \(0\)\
\-\ seizures\\:\\ 0\\.006323330236598689\ \(0\)\
\-\ calcified\\:\\ 0\\.00631329422917908\ \(0\)\
\-\ displacement\\:\\ 0\\.006303316401839448\ \(0\)\
\-\ for\\:\\ 0\\.006274596804154174\ \(0\)\
\-\ skull\\:\\ 0\\.00626397365127826\ \(0\)\
\-\ parenchyma\\:\\ 0\\.00626397365127826\ \(0\)\
\-\ external\\:\\ 0\\.0062542768910058754\ \(0\)\
\-\ characteristic\\:\\ 0\\.00622551014234195\ \(0\)\
\-\ \\(\\:\\ 0\\.006216538091599487\ \(0\)\
\-\ intracranial\\:\\ 0\\.006216027085868679\ \(0\)\
\-\ site\\:\\ 0\\.006216027085868679\ \(0\)\
\-\ multiple\\:\\ 0\\.00619554562299232\ \(0\)\
\-\ \\)\\:\\ 0\\.006140599760011231\ \(0\)\
\-\ around\\:\\ 0\\.006123963944817069\ \(0\)\
\-\ coronal\\:\\ 0\\.006123963944817069\ \(0\)\
\-\ administration\\:\\ 0\\.006106127822552788\ \(0\)\
\-\ arising\\:\\ 0\\.006088474638099795\ \(0\)\
\-\ arteries\\:\\ 0\\.006088474638099795\ \(0\)\
\-\ related\\:\\ 0\\.00607100067688806\ \(0\)\
\-\ formation\\:\\ 0\\.00607100067688806\ \(0\)\
\-\ located\\:\\ 0\\.006053702336348471\ \(0\)\
\-\ single\\:\\ 0\\.005961549553339814\ \(0\)\
\-\ sagittal\\:\\ 0\\.005866345357153837\ \(0\)\
\-\ vertebral\\:\\ 0\\.00582064788366998\ \(0\)\
\-\ hypertension\\:\\ 0\\.0057982462173841445\ \(0\)\
\-\ pressure\\:\\ 0\\.005776132374909362\ \(0\)\
\-\ base\\:\\ 0\\.005761546097816466\ \(0\)\
\-\ rate\\:\\ 0\\.005732739226292329\ \(0\)\
\-\ rare\\:\\ 0\\.005711446125083126\ \(0\)\
\-\ images\\:\\ 0\\.005642904963681081\ \(0\)\
\-\ based\\:\\ 0\\.005608761380838143\ \(0\)\
\-\ grade\\:\\ 0\\.00560212873141303\ \(0\)\
\-\ occur\\:\\ 0\\.005518152545235007\ \(0\)\
\-\ which\\:\\ 0\\.00549103128138571\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.005462325908826823\ \(0\)\
\-\ intensity\\:\\ 0\\.0053161285307733236\ \(0\)\
\-\ 20\\:\\ 0\\.005288322265330492\ \(0\)\
\-\ identified\\:\\ 0\\.005255537076052188\ \(0\)\
\-\ extension\\:\\ 0\\.005250133082928836\ \(0\)\
\-\ the\\:\\ 0\\.005234912673803387\ \(0\)\
\-\ would\\:\\ 0\\.005234022165958847\ \(0\)\
\-\ effect\\:\\ 0\\.005207501296160491\ \(0\)\
\-\ new\\:\\ 0\\.005125280510844335\ \(0\)\
\-\ was\\:\\ 0\\.005102982042411464\ \(0\)\
\-\ that\\:\\ 0\\.005080828669737774\ \(0\)\
\-\ benign\\:\\ 0\\.005075818187664718\ \(0\)\
\-\ headache\\:\\ 0\\.005051610047445435\ \(0\)\
\-\ does\\:\\ 0\\.005018280671917395\ \(0\)\
\-\ thickening\\:\\ 0\\.004985584457303531\ \(0\)\
\-\ masses\\:\\ 0\\.004971759721163662\ \(0\)\
\-\ type\\:\\ 0\\.004958045143454235\ \(0\)\
\-\ and\\:\\ 0\\.0049572187464982705\ \(0\)\
\-\ followed\\:\\ 0\\.004930939537657094\ \(0\)\
\-\ internal\\:\\ 0\\.004930939537657094\ \(0\)\
\-\ size\\:\\ 0\\.004930939537657094\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.00489545023093982\ \(0\)\
\-\ vascular\\:\\ 0\\.004822380839799822\ \(0\)\
\-\ 2\\.\\:\\ 0\\.004677184409294765\ \(0\)\
\-\ past\\:\\ 0\\.004673320949993863\ \(0\)\
\-\ t1\\:\\ 0\\.004661782334293018\ \(0\)\
\-\ between\\:\\ 0\\.004661782334293018\ \(0\)\
\-\ enhancing\\:\\ 0\\.004612656683106299\ \(0\)\
\-\ of\\:\\ 0\\.004612026537614\ \(0\)\
\-\ medical\\:\\ 0\\.004525490189442348\ \(0\)\
\-\ clinical\\:\\ 0\\.004525490189442348\ \(0\)\
\-\ show\\:\\ 0\\.0045148983381955695\ \(0\)\
\-\ age\\:\\ 0\\.00447660985463736\ \(0\)\
\-\ yo\\:\\ 0\\.004425734119281863\ \(0\)\
\-\ month\\:\\ 0\\.004412417454045799\ \(0\)\
\-\ negative\\:\\ 0\\.0043926336684593364\ \(0\)\
\-\ artery\\:\\ 0\\.004379569693817899\ \(0\)\
\-\ years\\:\\ 0\\.004318835003474152\ \(0\)\
\-\ not\\:\\ 0\\.004250666684137472\ \(0\)\
\-\ two\\:\\ 0\\.004212274075070578\ \(0\)\
\-\ focal\\:\\ 0\\.004200505342751122\ \(0\)\
\-\ abnormal\\:\\ 0\\.00419465101603255\ \(0\)\
\-\ following\\:\\ 0\\.0041743162769382934\ \(0\)\
\-\ t2\\:\\ 0\\.0041628033885548225\ \(0\)\
\-\ all\\:\\ 0\\.004159937159090001\ \(0\)\
\-\ he\\:\\ 0\\.004103592671313287\ \(0\)\
\-\ mass\\:\\ 0\\.004091087803606074\ \(0\)\
\-\ history\\:\\ 0\\.00406270064615175\ \(0\)\
\-\ blood\\:\\ 0\\.004014476889000516\ \(0\)\
\-\ if\\:\\ 0\\.003990952553839304\ \(0\)\
\-\ significant\\:\\ 0\\.00395498649062689\ \(0\)\
\-\ up\\:\\ 0\\.00395498649062689\ \(0\)\
\-\ therapy\\:\\ 0\\.00393225610368436\ \(0\)\
\-\ signal\\:\\ 0\\.0038779248369583113\ \(0\)\
\-\ mild\\:\\ 0\\.0038730696281086695\ \(0\)\
\-\ than\\:\\ 0\\.0038537846039901446\ \(0\)\
\-\ who\\:\\ 0\\.003834713268746475\ \(0\)\
\-\ anterior\\:\\ 0\\.003787939455701786\ \(0\)\
\-\ both\\:\\ 0\\.003755938021834977\ \(0\)\
\-\ symptoms\\:\\ 0\\.0036655034025785526\ \(0\)\
\-\ consistent\\:\\ 0\\.0036063653508282326\ \(0\)\
\-\ upper\\:\\ 0\\.003549191919739619\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.0035451798657181463\ \(0\)\
\-\ \\;\\:\\ 0\\.003486094988730798\ \(0\)\
\-\ man\\:\\ 0\\.003478368060395868\ \(0\)\
\-\ without\\:\\ 0\\.003463017498034699\ \(0\)\
\-\ 3\\:\\ 0\\.003444019839426058\ \(0\)\
\-\ demonstrate\\:\\ 0\\.0033845992105560082\ \(0\)\
\-\ mri\\:\\ 0\\.003379132280403821\ \(0\)\
\-\ can\\:\\ 0\\.0033360109336817035\ \(0\)\
\-\ present\\:\\ 0\\.0033218739310355953\ \(0\)\
\-\ contrast\\:\\ 0\\.0032922128860721264\ \(0\)\
\-\ demonstrates\\:\\ 0\\.003212773152587239\ \(0\)\
\-\ lateral\\:\\ 0\\.003178430371126593\ \(0\)\
\-\ 2\\:\\ 0\\.0031671333846997355\ \(0\)\
\-\ female\\:\\ 0\\.0030236837718551355\ \(0\)\
\-\ also\\:\\ 0\\.00289951737292625\ \(0\)\
\-\ as\\:\\ 0\\.0022247461375114077\ \(0\)\
\-\ there\\:\\ 0\\.002188839167753853\ \(0\)\
\-\ ct\\:\\ 0\\.002057321262292673\ \(0\)\
\-\ at\\:\\ 0\\.0019927076640819845\ \(0\)\
\-\ with\\:\\ 0\\.0018124571167108564\ \(0\)\
\-\ left\\:\\ 0\\.0016456200848070821\ \(0\)\
\-\ \\.\\:\\ 0\\.0015886195155438952\ \(0\)\
\-\ right\\:\\ 0\\.0015518618056977913\ \(0\)\
